A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)
Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.
- Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Nexavar®. The patients should have sufficient knowledge of French or Dutch to be able to participate in the Study
- Exclusion criteria must be read in conjunction with the Belgian product information
Many Locations, Belgium
E-mail: [email protected]
Phone: Not Available
Prospective open-label non-interventional, non-controlled multi observational and pharmaco-economic phase IV trial to evaluate the characteristics of patients treated for advanced renal cell carcinoma with Nexavar ® as well as effectiveness, safety and direct medical costs of Nexavar® treatment under daily-life treatment conditions